CytomX Therapeutics (NASDAQ:CTMX) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

CytomX Therapeutics (NASDAQ:CTMX) posted its earnings results on Thursday. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), Zacks reports. CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 45.40%. The company had revenue of $1.42 million during the quarter, compared to analysts’ expectations of $12.39 million.

Here are the key takeaways from CytomX Therapeutics’ conference call:

• Varseta-M dose-optimization enrollment is complete, with a 113-patient Phase I study ongoing; CytomX expects to report broader monotherapy data, including initial progression-free and overall-survival information, by year-end 2026 and start a potential registrational study in the first half of 2027.
• The company is expanding Varseta-M into earlier-line colorectal cancer through bevacizumab and 5-FU/leucovorin combinations, with initial combination data expected in the first half of 2027 and a goal of replacing irinotecan in second-line treatment.
• CytomX is broadening Varseta-M into gastric/GEJ, pancreatic, and biliary tract cancers through new Phase I expansion cohorts, potentially positioning the drug as a pan-gastrointestinal ADC.
• CytomX received a $37 million Regeneron payment in July for two additional collaboration targets, taking pro forma cash to approximately $367 million; management projects cash runway into at least the second half of 2028.
• Diarrhea remains a key development risk for Varseta-M, particularly if Grade 3 rates trend toward the high end of the company’s 10%–20% risk-benefit range, which could affect its movement into earlier treatment lines despite reported improvement with loperamide and budesonide prophylaxis.

CytomX Therapeutics Stock Performance

CTMX stock traded up $0.09 on Friday, reaching $3.46. The company had a trading volume of 2,461,314 shares, compared to its average volume of 3,128,085. The company has a market cap of $588.86 million, a P/E ratio of -6.92 and a beta of 2.12. CytomX Therapeutics has a 1 year low of $1.72 and a 1 year high of $8.21. The company’s fifty day moving average is $3.35 and its 200 day moving average is $4.27.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Zacks Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. HC Wainwright decreased their price objective on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Wolfe Research started coverage on shares of CytomX Therapeutics in a report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 target price on the stock. Wall Street Zen upgraded shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.10.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds have recently modified their holdings of the company. Evolve Private Wealth LLC purchased a new position in CytomX Therapeutics during the fourth quarter worth about $63,000. Mariner LLC raised its stake in CytomX Therapeutics by 116.4% during the fourth quarter. Mariner LLC now owns 22,180 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 11,930 shares during the period. Paces Ferry Wealth Advisors LLC acquired a new position in shares of CytomX Therapeutics in the 4th quarter valued at $63,000. State of Wyoming acquired a new position in shares of CytomX Therapeutics in the 4th quarter valued at $92,000. Finally, Jain Global LLC purchased a new stake in shares of CytomX Therapeutics during the 3rd quarter valued at $107,000. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.